Micro-cap ($170M) POC market leader, now #1 in US POC after ResMed (2021) and Philips (2024) exits. Balance sheet is the anchor: $110M cash, near-zero debt, net cash $3.44/sh = 55% of $6.25 price. Business in transition: US −5%, International +18%. Q1 26 Adj EBITDA slipped back to −$1.4M after achieving positive FY25 EBITDA. Base FV $13.0 vs price $6.25 → gap +108%, in line with analyst consensus $11–13. Risk/reward asymmetry driven by cash floor limiting downside, not by momentum.
SoTP is the appropriate method for a micro-cap in transition with negative EBITDA and >50% mkt cap in cash. Multiples derived from med-device small-cap peer set (BVS, ENOV, ITGR — median 1.7x EV/Rev fwd), with US business discounted heavily for structural revenue decline and INGN's own historical peak multiple (2.5x in 2018) as anchor for what recovery could unlock. Sensitivity: +/− 0.2x on blended multiple → +/− $2.7/sh; +/− 5% on international growth → +/− $0.5/sh. Cross-check consensus: median PT $12–13 within +5% of base FV → convergence. Cash floor $3.44/sh is the hard downside; equity can only compress below cash if operating losses burn it. ⚠️ Not investment advice.
| Component | Assumption | USD/share |
|---|---|---|
| US business (0.6x FY26E rev) | $310M × 0.6x = $186M ÷ 27M sh. (declining segment, lower multiple) | +6.89 |
| International (1.5x FY26E rev) | $60M × 1.5x = $90M ÷ 27M sh. (+18% YoY growth premium) | +3.33 |
| Net cash floor | ($110M cash − $17M debt) ÷ 27M sh. — hard downside anchor | +3.44 |
| EBITDA recovery option | 25% probability × $30M NPV (return to +$5M EBITDA by 2028) ÷ 27M sh. | +0.28 |
| SBC dilution (3Y) | 2%/yr × 3 = 6% dilution on equity value ($13.94 base × −6%) | −0.94 |
| FV base case | Sum of rows above | ≈ $13.00 |
Short interest 3.5% is below sector average — market is not shorting INGN, it is simply ignoring it (float dry). Combined with no buyback despite fortress cash, INGN suffers from micro-cap neglect: no forced sellers, no forced buyers. Any positive catalyst can move the stock disproportionately given the low float and low SI.
| Item | FY2023 | FY2024 | FY2025 | Q1 2026 | Guidance 2026 |
|---|---|---|---|---|---|
| Revenue ($M) | 289 | 335.7 | 348.7 | 85.1 | 366–373 |
| Revenue growth | — | +16.1% | +3.9% | +3.4% YoY | +5–7% |
| US revenue growth | — | flat | −2% | −5% | −3% (est.) |
| International rev growth | — | +8% | +15% | +18% | +18–20% |
| Adj EBITDA ($M) | −22 | −15 | +2 | −1.4 | improvement (guided, not quantified) |
| GAAP net income ($M) | −53 | −41 | −26 | −7 est. | still negative |
| Cash + securities ($M) | 127 | 120 | 115 | 111.5 | ~105–110 EoY |
| Total debt ($M) | 17 | 17 | 17 | 17 | 17 (no refi) |
| Net cash / share ($) | 4.15 | 3.85 | 3.60 | 3.44 | ~3.30 EoY |
| Metric | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 |
|---|---|---|---|---|---|
| Revenue ($M) | 82.3 | 92.5 | 92.4 | 81.5 | 85.1 |
| US rev ($M) | 62 | 70 | 68 | 60 | 59 |
| Intl rev ($M) | 20 | 22 | 24 | 21 | 26 |
| Adj EBITDA ($M) | 0.04 | 0.9 | 1.5 | −0.5 | −1.4 |
| Cash ($M) | 115 | 117 | 115 | 115 | 111.5 |
Business model — Portable oxygen concentrator platform
US direct-to-consumer ~$180M FY26E (~49% rev) 🔴 declining Historically the growth engine; now under pressure from softer patient acquisition, elevated CAC, and competition from cheaper Chinese POCs. Highest gross margin channel but structurally shrinking. US B2B (HME rental) ~$130M FY26E (~35% rev) 🟡 stable Rental to home medical equipment providers on Medicare reimbursement. Steady demand from CMS coverage but lower margin. Volume growth roughly offsetting price pressure. International distribution ~$60M FY26E (~16% rev) 🟢 ramping Europe (main), Asia-Pacific expansion. +18% YoY in Q1 26. Post-Philips exit created a vacuum in EU. Fastest growing segment, key long-term recovery vector for INGN.
Legal, regulatory and risk analysis
SWOT analysis
- +Fortress balance sheet: $93M net cash = 55% of market cap
- +#1 US POC market share (~50%) post ResMed/Philips exits
- +Zero material long-term debt, cash runway >10 years
- +International segment +18% YoY, ramping
- +FY25 achieved first positive Adj EBITDA since 2019
- −US DTC channel structurally declining (−5% YoY)
- −Q1 26 EBITDA slipped back to negative
- −No quantified FY26 EBITDA guidance — commitment vague
- −No buyback despite excess cash — capital allocation drag
- −Micro-cap illiquidity, low institutional coverage (3–7 analysts)
- →Philips POC vacuum in EU — direct beneficiary
- →Buyback authorization at cash-floor prices could unlock re-rating
- →M&A optionality: $93M cash could fund adjacencies
- →Aging population secular tailwind (COPD prevalence)
- →Analyst PT $11–13 implies +75–108% if execution improves
- !Chinese POC price competition on DTC
- !CMS reimbursement cycle risk (medium-term)
- !Continued cash burn if EBITDA path slips (10-year runway still finite)
- !Value trap risk if turnaround narrative fails to materialize
Summary by assessment area
- Net cash $93M = 55% of mkt cap
- Zero material long-term debt
- Cash runway >10 years — no going concern
- US −5% YoY, International +18% YoY
- #1 POC share, but structural DTC headwinds
- EBITDA slipped after brief positive run
- Base FV $13 vs price $6.25 (+108%)
- EV of $77M for $370M revenue biz
- Cash floor $3.44/sh caps downside
Sources: Inogen IR, Q1 2026 earnings release (May 2026), Q4/FY 2025 earnings release (Feb 2026), StockAnalysis, StockTitan, CNN Markets, Fintel, Kraken, SEC 10-K FY25. Market data — last verified close 2026-07-24: INGN ~$6.25, market cap ~$170M, 52W: $5.35 – $9.11, shares outstanding ~27M. Short interest: ~3.5%. Consensus PT $11–13 (3–7 analysts, mid Jul 2026). This document is for informational purposes only and does not constitute financial or investment advice.